Immunai Inc., a New York-based biotechnology company specializing in artificial intelligence, has formed a multi-year collaboration with global pharmaceutical giant AstraZeneca. The partnership aims to leverage Immunai’s proprietary AI model, the IDE, to enhance clinical decision-making and improve the success rates of drug development programs.   Under the terms of the agreement, AstraZeneca will provide Immunai with $18 million for the initial phase of the collaboration. The companies ...